Wegovy injections
Wegovy injection contains semaglutide and is taken once weekly. Its approved uses include weight management, cardiovascular risk reduction in qualifying adults, and treatment of qualifying noncirrhotic MASH. The injection, higher-dose presentation, and tablet have different indication and dose details.
Eligibility: Wegovy injections
For weight management, Wegovy injection is approved for adults with obesity, selected adults with overweight and a weight-related condition, and children 12 years and older with obesity. Cardiovascular and MASH indications apply to specified adults. Pediatric treatment needs age-appropriate care.
What to expect: Wegovy injections
Review the indication, risks, previous medicines, and ability to continue treatment. Start and increase the exact formulation under the prescriber’s plan. Learn injection use and storage for the device dispensed. Add nutrition support and agree on follow-up, side-effect reporting, and refills.
Preparing for your appointment
Bring your weight and treatment history, medicines and supplements, relevant glucose, kidney, and lipid results, and the exact product you have used before. Mention previous side effects, eye disease, eating difficulties, and pregnancy plans. If insurance denied treatment, bring the denial and plan details.
Risks and when to seek help
Review a personal or family history of medullary thyroid cancer, MEN 2, severe stomach-emptying problems, pancreatitis, gallbladder disease, allergies, and pregnancy plans before treatment. Nausea, vomiting, constipation, or diarrhea can occur. Persistent severe abdominal pain or inability to keep fluids down needs emergency department assessment now. Call 911 for breathing difficulty, a severe allergic reaction, loss of consciousness or unsafe travel. Tell the anesthesia team about treatment before a procedure. Do not combine GLP-1 medicines or change the dose yourself. For weight or cardiovascular risk treatment, discontinue when pregnancy is recognized and plan at least a two-month interval before pregnancy. The MASH label has separate benefit-risk language that needs specialist review.
Follow-up and treatment review
Review weight trend, appetite, food and fluid intake, bowel symptoms, and treatment tolerability. Check glucose and adjust other diabetes medicines with the prescriber when relevant. Agree on how to contact the team between visits and what to do if a refill is delayed. Continued treatment depends on benefit, safety, access, and your goals.
Appointments, costs and coverage
Confirm the exact service, clinician, formulation, appointment, and refill route before booking. The evaluation, tests, medicine, administration, and follow-up may have separate costs and benefits. Ask for current estimates and required records. An FDA-approved drug or a clinic address does not establish pharmacy stock, onsite treatment, coverage, or a prescription. If access changes, contact the treating team before interrupting treatment.
Questions about your care
Does Nao Medical accept Medicaid and Medicare for weight-loss visits? Can I find out about coverage before I schedule?
The visit, laboratory tests, and medicine can have different coverage rules. Ask the plan about the exact brand and indication, exclusions, prior authorization, required records, deductible, copay, and dispensing route. Bring a denial for review of its specific reason. Nao Medical or the prescriber cannot guarantee approval. Confirm current participation and costs before booking.
Will I need prior authorization for Wegovy?
Your plan may require prior authorization for the exact Wegovy formulation and indication. Ask which diagnosis, weight history, prior treatment or other records it requires and obtain the actual decision before relying on coverage. A prescription, manufacturer support or covered consultation does not guarantee approval or eliminate out-of-pocket costs.
How much does Wegovy injection cost without insurance?
As of October 9, 2026, eligible patients new to the Wegovy savings offer or NovoCare Pharmacy can use a starter-dose self-pay offer. The advertised price is $199 for each of the first two monthly fills at 0.25 or 0.5 mg, through December 31, 2026. The advertised regular price is $349 per month for 0.25–2.4 mg single-dose pens. The 7.2 mg Wegovy HD pen is $399 per month. These are manufacturer program prices, subject to terms, rather than a guaranteed pharmacy bill. Ask the dispensing pharmacy for your exact prescription’s price and confirm visit and test charges separately.
Who qualifies for the advertised $25 Wegovy offer?
The as-little-as-$25 offer is for eligible patients whose commercial insurance covers Wegovy, subject to the manufacturer’s current terms. It requires a valid prescription for an FDA-approved use. As of October 9, 2026, maximum savings are $100 per month, so the offer may not reduce your copay to $25. Medicare, Medicaid and other government-program beneficiaries are excluded from this commercial savings offer. An uninsured patient uses a different self-pay program. Confirm eligibility, covered formulation, pharmacy processing and your actual charge before filling. A prescription alone does not qualify you.
Facebook
Instagram
Twitter
LinkedIn